The Challenge to Deliver Oxaliplatin (l-OHP) to Solid Tumors: Development of Liposomal l-OHP Formulations

Nana Cristina Amorim Matsuo; Hidenori Ando; Yusuke Doi; Taro Shimizu; Yu Ishima; Tatsuhiro Ishida

doi:10.1248/cpb.c22-00099

Current Topics: Reviews

The Challenge to Deliver Oxaliplatin (l-OHP) to Solid Tumors: Development of Liposomal l-OHP Formulations

Nana Cristina Amorim Matsuo, Hidenori Ando , Yusuke Doi, Taro Shimizu, Yu Ishima, Tatsuhiro Ishida

Author information

Keywords: oxaliplatin (l-OHP), drug delivery system (DDS), PEGylated liposome, cancer therapy

JOURNAL FREE ACCESS FULL-TEXT HTML

2022 Volume 70 Issue 5 Pages 351-358

DOI https://doi.org/10.1248/cpb.c22-00099

Details

Abstract

Oxaliplatin (l-OHP) is a third-generation platinum (Pt) agent approved for the treatment of patients with advanced colorectal cancer. Despite the fact that l-OHP has shown clinical therapeutic efficacy and better tolerability compared with other Pt agents, the use of l-OHP has been limited to clinical settings because of dose-limiting side effects such as cumulative neurotoxicity and acute dysesthesias, which can be severe. In preclinical and clinical studies, our group and several others have attempted the delivery of l-OHP to solid tumors via encapsulation in PEGylated liposomes. Herein, we review these attempts.

Fullsize Image

Corresponding author

Register with J-STAGE for free!